Search for a trial

A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome

Primary Study Objective: To evaluate the effect of telotristat etiprate versus placebo over the double-blind portion of the study on the incidence of treatment-emergent adverse events (TEAEs)

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Capecitabine and Cisplatin With or Without Ramucirumab as First-line Therapy in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (RAINFALL)

The primary objective of this study is to compare PFS of ramucirumab in combination with capecitabine (or 5-fluorouracil [5-FU]) and cisplatin versus placebo in combination with capecitabine (or 5-FU) and cisplatin as first-line treatment in…

*Effect of omega-3 fatty acids on the perioperative immune response and erythrocyte function*

Our primary objective is to study the effect of perioperative intravenous supplementation of omega-3 fatty acids on the perioperative inflammatory response compared to a saline control in patients undergoing surgery for colon cancer.

Stimulation of the autonomic nervous system in colorectal surgery by perioperative nutrition

The main objective is to investigate the effects of perioperative nutrition on postoperative ileus and anastomotic leakage in patients undergoing colorectal surgery

A Randomized, Double-Blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine

The primary objective of this study is to compare overall survival (OS) in patients with metastatic colorectal carcinoma (CRC) when treated with FOLFIRI in combination with placebo versus FOLFIRI in combination with ramucirumab DP.Secondary…

A randomized, double-blind, placebo-controlled phase III study of regorafenib plus BSC versus placebo plus BSC in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy

To evaluate efficacy and safety of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapies.The primary efficacy endpoint of this study is * Overall survivalThe secondary efficacy endpoints of this…

Laxatives postoperative colorectal surgery

The objective of this trial is to compare time to gastrointestinal recovery after elective colorectal surgery between patients treated with a laxative versus patients treated with a placebo.

A double-blind, randomised, placebo controlled Phase III study of
nintedanib plus best supportive care (BSC) versus placebo plus BSC in
patients with colorectal cancer refractory to standard therapies.

The objective of this Phase III study is to evaluate the efficacy and safety of nintedanib in patients with mCRC after failure of previous treatment with standard chemotherapy and biological agents.

A Phase 3, Randomized, Placebo-controlled, Parallel-group, Multicenter, Double-blind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome Not Adequately Controlled by Somatostatin Analog (SSA) Therapy

The primary objective of the study is to confirm that at least 1 or more doses of telotristat etiprate compared to placebo is effective in reducing the change from baseline in the number of daily bowel movements (BMs) averaged over the 12-week…

A phase I study assessing the safety and performance of VB5-845D-800CW, an anti-Epcam fluorescent agent, for the intraoperative detection of gastrointestinal cancer

Part A: healthy volunteers Primary objective- To determine safety and tolerability of a single dose of VB5-845D-800CW in healthy volunteers.Secondary objective- To determine the pharmacokinetics of VB5-845D-800CW by measuring fluorescence in blood…

Double-blind, randomised, placebo-controlled, phase IIa trial on the efficacy and tolerability of an 8-week treatment with two different doses of budesonide orodispersible tablets vs. placebo for prevention of oesophageal strictures in adult patients after endoscopic submucosal dissection

This study has been transitioned to CTIS with ID 2023-507897-42-00 check the CTIS register for the current data. The objective of the study is to investigate whether the use of budesonde orodispergible tablets after ESD can prevent the devolpment of…

A Randomized, Double-blind, Placebo-controlled, Phase III Study of Neoadjuvant-Adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab or Placebo in Patients with Resectable Gastric and Gastroesophageal Cancer (GC/GEJC) (MATTERHORN)

This study has been transitioned to CTIS with ID 2023-507338-26-00 check the CTIS register for the current data. Primary objective:To compare Arm A relative to Arm B on event-free survival (EFS)Key secondary objectives:- To compare Arm A relative to…

Intraoperative Music to PROMote PaTient oUtcome (IMPROMPTU): a double-blind, placebo-controlled, randomized multicenter trial

The main objective of this study is to investigate whether intraoperative music reduces postoperative pain in patients undergoing surgery for esophageal or stomach cancer. Secondary objectives are the effects of intraoperative music on…

A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects with Resected Esophageal, or Gastroesophageal Junction Cancer

This study has been transitioned to CTIS with ID 2023-509360-24-00 check the CTIS register for the current data. Primary objectives: This study has co-primary objectives:• To compare OS of nivolumab versus placebo in subjects with resected EC or GEJ…

A randomized controlled trial on the effect of beetroot juice on VO2max in patients undergoing a minimally invasive esophagectomy

The primary aim of this study is to investigate the added effect of one consecutive week of BRJ consumption on VO2max in prehabilitated patients scheduled to undergo a minimally invasive esophagectomy for cancer.

Phase III Double-blinded, Placebo Controlled Study of Xilonix* for Improving Survival in Metastatic Colorectal Cancer

The study will compare the overall survival (OS) between the MABp1 treated and placebo arms. Secondary endpoints will include change in lean body mass from screening to the cycle 5 assessment and change in quality of life.